Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain

Background:  Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ‐opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open‐label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long‐term safety and tolerability of tapen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pain practice 2010-09, Vol.10 (5), p.416-427
Hauptverfasser: Wild, James E., Grond, Stefan, Kuperwasser, Brigitte, Gilbert, Jane, McCann, Bettyanne, Lange, Bernd, Steup, Achim, Häufel, Thomas, Etropolski, Mila S., Rauschkolb, Christine, Lange, Robert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 427
container_issue 5
container_start_page 416
container_title Pain practice
container_volume 10
creator Wild, James E.
Grond, Stefan
Kuperwasser, Brigitte
Gilbert, Jane
McCann, Bettyanne
Lange, Bernd
Steup, Achim
Häufel, Thomas
Etropolski, Mila S.
Rauschkolb, Christine
Lange, Robert
description Background:  Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ‐opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open‐label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long‐term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or hip osteoarthritis pain or low back pain. Methods:  Patients were randomized 4:1 to receive controlled, adjustable, oral, twice‐daily doses of tapentadol ER (100 to 250 mg) or oxycodone HCl controlled release (CR; 20 to 50 mg) for up to 1 year. Efficacy evaluations included assessments at each study visit of average pain intensity (11‐point numerical rating scale) over the preceding 24 hours. Treatment‐emergent adverse events (TEAEs) and discontinuations were monitored throughout the study. Results:  A total of 1,117 patients received at least 1 dose of study drug. Mean (standard error) pain intensity scores in the tapentadol ER and oxycodone CR groups, respectively, were 7.6 (0.05) and 7.6 (0.11) at baseline and decreased to 4.4 (0.09) and 4.5 (0.17) at endpoint. The overall incidence of TEAEs was 85.7% in the tapentadol ER group and 90.6% in the oxycodone CR group. In the tapentadol ER and oxycodone CR groups, respectively, TEAEs led to discontinuation in 22.1% and 36.8% of patients; gastrointestinal TEAEs led to discontinuation in 8.6% and 21.5% of patients. Conclusion:  Tapentadol ER (100 to 250 mg bid) was associated with better gastrointestinal tolerability than oxycodone HCl CR (20 to 50 mg bid) and provided sustainable relief of moderate to severe chronic knee or hip osteoarthritis or low back pain for up to 1 year.
doi_str_mv 10.1111/j.1533-2500.2010.00397.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_877593339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>762685059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4147-e0d2c6f4dfe9c2b9bdcf1f7a8a699507e48865c1a0e4732d1f47b520588e00aa3</originalsourceid><addsrcrecordid>eNqFkU9z0zAQxT0MDC2Fr8DoxslhJVmWfeBQMv0DuDRTwsBw0WzsdaPUtoLsTJMzXxw5Kbmii3be_t4e3osixmHCw3u_mnAlZSwUwERAUAFkrifbZ9HpcfF8P0OsIVMn0au-XwFwnUv5MjoRkILQXJxGfwrX3ccD-ZZ9w5qGHcOuYnPXkMeFbWwQXM3muKZuwMo17GI7UFdRxe6oIeyJ1c6zYUnsBju8pzZwo2O69K6zJSvcI_uI5QOboe1YQG_7gRz6YentYPu9_Dp6UWPT05un_yz6fnkxn17Hxe3Vp-l5EZcJT3RMUIkyrZOqprwUi3xRlTWvNWaY5rkCTUmWparkCJRoKSpeJ3qhBKgsIwBEeRa9O9xde_d7Q_1gWtuX1DTYkdv0JtNahXxk_l9SpyLNFKiRfPtEbhYtVWbtbYt-Z_4lHIAPB-DRNrQ77jmYsUmzMmNhZizMjE2afZNma2bns7swBX988NsQ3PboR_9gUi21Mj--XpnpzZdf1z8vP5tC_gV29KFT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>762685059</pqid></control><display><type>article</type><title>Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Wild, James E. ; Grond, Stefan ; Kuperwasser, Brigitte ; Gilbert, Jane ; McCann, Bettyanne ; Lange, Bernd ; Steup, Achim ; Häufel, Thomas ; Etropolski, Mila S. ; Rauschkolb, Christine ; Lange, Robert</creator><creatorcontrib>Wild, James E. ; Grond, Stefan ; Kuperwasser, Brigitte ; Gilbert, Jane ; McCann, Bettyanne ; Lange, Bernd ; Steup, Achim ; Häufel, Thomas ; Etropolski, Mila S. ; Rauschkolb, Christine ; Lange, Robert</creatorcontrib><description>Background:  Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ‐opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open‐label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long‐term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or hip osteoarthritis pain or low back pain. Methods:  Patients were randomized 4:1 to receive controlled, adjustable, oral, twice‐daily doses of tapentadol ER (100 to 250 mg) or oxycodone HCl controlled release (CR; 20 to 50 mg) for up to 1 year. Efficacy evaluations included assessments at each study visit of average pain intensity (11‐point numerical rating scale) over the preceding 24 hours. Treatment‐emergent adverse events (TEAEs) and discontinuations were monitored throughout the study. Results:  A total of 1,117 patients received at least 1 dose of study drug. Mean (standard error) pain intensity scores in the tapentadol ER and oxycodone CR groups, respectively, were 7.6 (0.05) and 7.6 (0.11) at baseline and decreased to 4.4 (0.09) and 4.5 (0.17) at endpoint. The overall incidence of TEAEs was 85.7% in the tapentadol ER group and 90.6% in the oxycodone CR group. In the tapentadol ER and oxycodone CR groups, respectively, TEAEs led to discontinuation in 22.1% and 36.8% of patients; gastrointestinal TEAEs led to discontinuation in 8.6% and 21.5% of patients. Conclusion:  Tapentadol ER (100 to 250 mg bid) was associated with better gastrointestinal tolerability than oxycodone HCl CR (20 to 50 mg bid) and provided sustainable relief of moderate to severe chronic knee or hip osteoarthritis or low back pain for up to 1 year.</description><identifier>ISSN: 1530-7085</identifier><identifier>EISSN: 1533-2500</identifier><identifier>DOI: 10.1111/j.1533-2500.2010.00397.x</identifier><identifier>PMID: 20602712</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Aged ; analgesics ; Analgesics, Opioid - therapeutic use ; Delayed-Action Preparations - therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Longitudinal Studies ; low back pain ; Low Back Pain - drug therapy ; Male ; Middle Aged ; opioid ; Osteoarthritis - complications ; Osteoarthritis - drug therapy ; Pain Measurement ; Patient Compliance ; Phenols - administration &amp; dosage</subject><ispartof>Pain practice, 2010-09, Vol.10 (5), p.416-427</ispartof><rights>2010 World Institute of Pain</rights><rights>2010 World Institute of Pain.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4147-e0d2c6f4dfe9c2b9bdcf1f7a8a699507e48865c1a0e4732d1f47b520588e00aa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1533-2500.2010.00397.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1533-2500.2010.00397.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20602712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wild, James E.</creatorcontrib><creatorcontrib>Grond, Stefan</creatorcontrib><creatorcontrib>Kuperwasser, Brigitte</creatorcontrib><creatorcontrib>Gilbert, Jane</creatorcontrib><creatorcontrib>McCann, Bettyanne</creatorcontrib><creatorcontrib>Lange, Bernd</creatorcontrib><creatorcontrib>Steup, Achim</creatorcontrib><creatorcontrib>Häufel, Thomas</creatorcontrib><creatorcontrib>Etropolski, Mila S.</creatorcontrib><creatorcontrib>Rauschkolb, Christine</creatorcontrib><creatorcontrib>Lange, Robert</creatorcontrib><title>Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain</title><title>Pain practice</title><addtitle>Pain Pract</addtitle><description>Background:  Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ‐opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open‐label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long‐term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or hip osteoarthritis pain or low back pain. Methods:  Patients were randomized 4:1 to receive controlled, adjustable, oral, twice‐daily doses of tapentadol ER (100 to 250 mg) or oxycodone HCl controlled release (CR; 20 to 50 mg) for up to 1 year. Efficacy evaluations included assessments at each study visit of average pain intensity (11‐point numerical rating scale) over the preceding 24 hours. Treatment‐emergent adverse events (TEAEs) and discontinuations were monitored throughout the study. Results:  A total of 1,117 patients received at least 1 dose of study drug. Mean (standard error) pain intensity scores in the tapentadol ER and oxycodone CR groups, respectively, were 7.6 (0.05) and 7.6 (0.11) at baseline and decreased to 4.4 (0.09) and 4.5 (0.17) at endpoint. The overall incidence of TEAEs was 85.7% in the tapentadol ER group and 90.6% in the oxycodone CR group. In the tapentadol ER and oxycodone CR groups, respectively, TEAEs led to discontinuation in 22.1% and 36.8% of patients; gastrointestinal TEAEs led to discontinuation in 8.6% and 21.5% of patients. Conclusion:  Tapentadol ER (100 to 250 mg bid) was associated with better gastrointestinal tolerability than oxycodone HCl CR (20 to 50 mg bid) and provided sustainable relief of moderate to severe chronic knee or hip osteoarthritis or low back pain for up to 1 year.</description><subject>Adult</subject><subject>Aged</subject><subject>analgesics</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>low back pain</subject><subject>Low Back Pain - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>opioid</subject><subject>Osteoarthritis - complications</subject><subject>Osteoarthritis - drug therapy</subject><subject>Pain Measurement</subject><subject>Patient Compliance</subject><subject>Phenols - administration &amp; dosage</subject><issn>1530-7085</issn><issn>1533-2500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9z0zAQxT0MDC2Fr8DoxslhJVmWfeBQMv0DuDRTwsBw0WzsdaPUtoLsTJMzXxw5Kbmii3be_t4e3osixmHCw3u_mnAlZSwUwERAUAFkrifbZ9HpcfF8P0OsIVMn0au-XwFwnUv5MjoRkILQXJxGfwrX3ccD-ZZ9w5qGHcOuYnPXkMeFbWwQXM3muKZuwMo17GI7UFdRxe6oIeyJ1c6zYUnsBju8pzZwo2O69K6zJSvcI_uI5QOboe1YQG_7gRz6YentYPu9_Dp6UWPT05un_yz6fnkxn17Hxe3Vp-l5EZcJT3RMUIkyrZOqprwUi3xRlTWvNWaY5rkCTUmWparkCJRoKSpeJ3qhBKgsIwBEeRa9O9xde_d7Q_1gWtuX1DTYkdv0JtNahXxk_l9SpyLNFKiRfPtEbhYtVWbtbYt-Z_4lHIAPB-DRNrQ77jmYsUmzMmNhZizMjE2afZNma2bns7swBX988NsQ3PboR_9gUi21Mj--XpnpzZdf1z8vP5tC_gV29KFT</recordid><startdate>201009</startdate><enddate>201009</enddate><creator>Wild, James E.</creator><creator>Grond, Stefan</creator><creator>Kuperwasser, Brigitte</creator><creator>Gilbert, Jane</creator><creator>McCann, Bettyanne</creator><creator>Lange, Bernd</creator><creator>Steup, Achim</creator><creator>Häufel, Thomas</creator><creator>Etropolski, Mila S.</creator><creator>Rauschkolb, Christine</creator><creator>Lange, Robert</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>201009</creationdate><title>Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain</title><author>Wild, James E. ; Grond, Stefan ; Kuperwasser, Brigitte ; Gilbert, Jane ; McCann, Bettyanne ; Lange, Bernd ; Steup, Achim ; Häufel, Thomas ; Etropolski, Mila S. ; Rauschkolb, Christine ; Lange, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4147-e0d2c6f4dfe9c2b9bdcf1f7a8a699507e48865c1a0e4732d1f47b520588e00aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>analgesics</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>low back pain</topic><topic>Low Back Pain - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>opioid</topic><topic>Osteoarthritis - complications</topic><topic>Osteoarthritis - drug therapy</topic><topic>Pain Measurement</topic><topic>Patient Compliance</topic><topic>Phenols - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wild, James E.</creatorcontrib><creatorcontrib>Grond, Stefan</creatorcontrib><creatorcontrib>Kuperwasser, Brigitte</creatorcontrib><creatorcontrib>Gilbert, Jane</creatorcontrib><creatorcontrib>McCann, Bettyanne</creatorcontrib><creatorcontrib>Lange, Bernd</creatorcontrib><creatorcontrib>Steup, Achim</creatorcontrib><creatorcontrib>Häufel, Thomas</creatorcontrib><creatorcontrib>Etropolski, Mila S.</creatorcontrib><creatorcontrib>Rauschkolb, Christine</creatorcontrib><creatorcontrib>Lange, Robert</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><jtitle>Pain practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wild, James E.</au><au>Grond, Stefan</au><au>Kuperwasser, Brigitte</au><au>Gilbert, Jane</au><au>McCann, Bettyanne</au><au>Lange, Bernd</au><au>Steup, Achim</au><au>Häufel, Thomas</au><au>Etropolski, Mila S.</au><au>Rauschkolb, Christine</au><au>Lange, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain</atitle><jtitle>Pain practice</jtitle><addtitle>Pain Pract</addtitle><date>2010-09</date><risdate>2010</risdate><volume>10</volume><issue>5</issue><spage>416</spage><epage>427</epage><pages>416-427</pages><issn>1530-7085</issn><eissn>1533-2500</eissn><abstract>Background:  Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ‐opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open‐label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long‐term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or hip osteoarthritis pain or low back pain. Methods:  Patients were randomized 4:1 to receive controlled, adjustable, oral, twice‐daily doses of tapentadol ER (100 to 250 mg) or oxycodone HCl controlled release (CR; 20 to 50 mg) for up to 1 year. Efficacy evaluations included assessments at each study visit of average pain intensity (11‐point numerical rating scale) over the preceding 24 hours. Treatment‐emergent adverse events (TEAEs) and discontinuations were monitored throughout the study. Results:  A total of 1,117 patients received at least 1 dose of study drug. Mean (standard error) pain intensity scores in the tapentadol ER and oxycodone CR groups, respectively, were 7.6 (0.05) and 7.6 (0.11) at baseline and decreased to 4.4 (0.09) and 4.5 (0.17) at endpoint. The overall incidence of TEAEs was 85.7% in the tapentadol ER group and 90.6% in the oxycodone CR group. In the tapentadol ER and oxycodone CR groups, respectively, TEAEs led to discontinuation in 22.1% and 36.8% of patients; gastrointestinal TEAEs led to discontinuation in 8.6% and 21.5% of patients. Conclusion:  Tapentadol ER (100 to 250 mg bid) was associated with better gastrointestinal tolerability than oxycodone HCl CR (20 to 50 mg bid) and provided sustainable relief of moderate to severe chronic knee or hip osteoarthritis or low back pain for up to 1 year.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>20602712</pmid><doi>10.1111/j.1533-2500.2010.00397.x</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1530-7085
ispartof Pain practice, 2010-09, Vol.10 (5), p.416-427
issn 1530-7085
1533-2500
language eng
recordid cdi_proquest_miscellaneous_877593339
source MEDLINE; Access via Wiley Online Library
subjects Adult
Aged
analgesics
Analgesics, Opioid - therapeutic use
Delayed-Action Preparations - therapeutic use
Double-Blind Method
Drug Administration Schedule
Female
Humans
Longitudinal Studies
low back pain
Low Back Pain - drug therapy
Male
Middle Aged
opioid
Osteoarthritis - complications
Osteoarthritis - drug therapy
Pain Measurement
Patient Compliance
Phenols - administration & dosage
title Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A35%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20Safety%20and%20Tolerability%20of%20Tapentadol%20Extended%20Release%20for%20the%20Management%20of%20Chronic%20Low%20Back%20Pain%20or%20Osteoarthritis%20Pain&rft.jtitle=Pain%20practice&rft.au=Wild,%20James%20E.&rft.date=2010-09&rft.volume=10&rft.issue=5&rft.spage=416&rft.epage=427&rft.pages=416-427&rft.issn=1530-7085&rft.eissn=1533-2500&rft_id=info:doi/10.1111/j.1533-2500.2010.00397.x&rft_dat=%3Cproquest_pubme%3E762685059%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=762685059&rft_id=info:pmid/20602712&rfr_iscdi=true